1. Home
  2. NCPL vs SNGX Comparison

NCPL vs SNGX Comparison

Compare NCPL & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NCPL

Netcapital Inc.

HOLD

Current Price

$0.70

Market Cap

7.1M

Sector

Finance

ML Signal

HOLD

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$0.40

Market Cap

5.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCPL
SNGX
Founded
1984
1987
Country
United States
United States
Employees
20
14
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
5.9M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
NCPL
SNGX
Price
$0.70
$0.40
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
7.4M
10.2M
Earning Date
03-19-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.03
EPS
N/A
N/A
Revenue
N/A
$119,371.00
Revenue This Year
$739.37
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.28
52 Week High
$8.75
$6.23

Technical Indicators

Market Signals
Indicator
NCPL
SNGX
Relative Strength Index (RSI) 46.11 39.82
Support Level $0.59 $0.28
Resistance Level $0.84 $0.41
Average True Range (ATR) 0.13 0.05
MACD -0.06 -0.01
Stochastic Oscillator 13.35 0.56

Price Performance

Historical Comparison
NCPL
SNGX

About NCPL Netcapital Inc.

Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

Share on Social Networks: